---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-279108"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:31:12.650227+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Verrica Q3 net income $83K; reiterates VP-102 NDA resubmission in Q1 2023

## Summary
- Q3 GAAP net income of $83K ($0.00/sh) vs net loss of $12.8M in Q3 2021; non-GAAP net income $2.9M ($0.07/sh).
- License revenue of $8.3M from Torii milestone; cash, equivalents and marketable securities total $39.5M.
- Reiterates plan to resubmit NDA for VP-102 (molluscum contagiosum) in Q1 2023.
- Phase 2 trial of VP-LTX-315 (basal cell carcinoma) Part 1 expected to conclude in Q1 2023.
- R&D and G&A expenses declined vs prior year due to reduced headcount and lower CMC costs.

## SEC filing metadata
- accession: 0001193125-22-279108
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312522279108/0001193125-22-279108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312522279108/d397144d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-279108
- JSON: https://secwatch.observer/filing/0001193125-22-279108.json
- Plain text: https://secwatch.observer/filing/0001193125-22-279108.txt

## Key facts
- Earnings Releases
  Verrica Pharmaceuticals Inc. reported nine months ended September 30, 2022 results: revenue $9.0 million, net income net loss of $18.6 million, EPS $0.58 per share.
  - Period: nine months ended September 30, 2022
  - Revenue: $9.0 million
  - Net income: net loss of $18.6 million
  - EPS: $0.58 per share
  - Result: reported results
  source text: million, or $0.40 per share, for the same period in 2021. Year-to-Date September 2022 Financial Results • Verrica recognized license revenues related to the Torii Agreement of $9.0 million for the nine months ended September 30, 2022 compared to $12.0 million for the same period in 2021. The current period license revenue was related to an $8.0 million milestone
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312522279108/0001193125-22-279108-index.htm
- Earnings Releases
  Verrica Pharmaceuticals Inc. reported the third quarter ended September 30, 2022 results: revenue $8.3 million, net income $83 thousand, EPS $0.00 per share.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $8.3 million
  - Net income: $83 thousand
  - EPS: $0.00 per share
  - Result: reported results
  source text: Part 1 (safety and dose escalation) is expected to conclude in Q1 2023. Financial Results Third Quarter 2022 Financial Results • Verrica recognized license revenues of $8.3 million for the three months ended September 30, 2022 and no license revenue for the same period in 2021 related to the Collaboration and License Agreement (the “Torii Agreement”) with
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312522279108/0001193125-22-279108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.